AstraZeneca's Tagrisso Shows Major PFS Benefit (HR=0.16) in Stage III Lung Cancer Laura Trial

Jun 2, 2024, 12:56 PM

At the ASCO 2024 conference, AstraZeneca reported significant findings regarding its drug Tagrisso and its impact on stage III non-small cell lung cancer (NSCLC) with EGFR mutations. The Laura trial demonstrated a massive progression-free survival (PFS) benefit with a hazard ratio of 0.16. However, the study noted an 81% rate of placebo patient crossover, effectively making it a comparison of maintenance Tagrisso versus Tagrisso on progression. Osimertinib could alter the standard of care (SOC) for stage III EGFR+ NSCLC, according to Dr. Ramalingam. These findings highlight the potential of targeted therapies in improving cancer treatment outcomes.